Axe-Bio

Axe-Bio is an early-stage biotechnology company dedicated to developing a novel class of tRNA-based therapeutics designed to treat genetic diseases caused by nonsense mutations. By engineering specialized transfer RNAs (tRNAs), the company aims to enable the cellular machinery to read through premature stop codons, thereby restoring the production of full-length, functional proteins. This approach has the potential to address a wide range of indications, including rare genetic disorders and certain types of cancer where nonsense mutations are a primary driver. Axe-Bio's platform focuses on optimizing the delivery and efficacy of these engineered tRNAs to provide transformative treatments for patients with high unmet medical needs.